Prab: CSV import

2025-02-20T01:13:29Z

CSV import

← Older revision		Revision as of 01:13, 20 February 2025
Line 18:		Line 18:
	{{anticholinergic agents}}		{{anticholinergic agents}}
	{{coststubd}}		{{coststubd}}
			<gallery>
			File:Mepenzolate.png\|Mepenzolate
			</gallery>

Prab: Created page with "{{intro}} Mepenzolate is an anticholinergic agent used to treat gastrointestinal conditions such as acid peptic disease and irritable bowel syndrome. {{livtox}} Mepenzolate ..."

2019-04-25T20:46:48Z

Created page with "{{intro}} Mepenzolate is an anticholinergic agent used to treat gastrointestinal conditions such as acid peptic disease and irritable bowel syndrome. {{livtox}} Mepenzolate ..."

New page

{{intro}}
Mepenzolate is an anticholinergic agent used to treat gastrointestinal conditions such as acid peptic disease and irritable bowel syndrome.

{{livtox}}
Mepenzolate has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.

{{moa}}
Mepenzolate (me pen' zoe late) is a synthetic quaternary ammonium anticholinergic agent which inhibits the muscarinic actions of [[acetylcholine]] on autonomic nerve endings, decreasing gastrointestinal secretions and intestinal motility. Mepenzolate has broad activity against muscarinic [[acetylcholine]] receptors, but its highly polar quaternary ammonium group makes it less likely to cross lipid membranes such as the blood brain barrier, which is believed to decrease the potential for central nervous system effects. Mepenzolate has been used largely for gastrointestinal conditions including peptic ulcer disease and gastrointestinal conditions associated with pain and spasm.

{{fda}}
Mepenzolate is approved for use in the United States for the treatment of peptic ulcer disease but is now not commonly used, having been replaced by more effective antiulcer agents. Mepenzolate is available in tablets 25 mg under the brand name Cantil.

{{dose}}
The typically recommended oral dose in adults is 25 to 50 mg two to four times daily.

{{se}}
Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, [[headache]], [[visual blurring]], [[constipation]], and [[urinary retention]]. Because of its structure, mepenzolate is believed to be less likely than other anticholinergics to cross the blood brain barrier and cause central nervous system effects such as [[restlessness]], confusion and hallucinations. Anticholinergic agents can precipitate acute narrow angle glaucoma and acute [[urinary retention]].
{{anticholinergic agents}}
{{coststubd}}

Mepenzolate - Revision history

Prab: CSV import

Prab: Created page with "{{intro}} Mepenzolate is an anticholinergic agent used to treat gastrointestinal conditions such as acid peptic disease and irritable bowel syndrome. {{livtox}} Mepenzolate ..."